David A. Griffith

3.5k total citations · 1 hit paper
52 papers, 2.5k citations indexed

About

David A. Griffith is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, David A. Griffith has authored 52 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 17 papers in Organic Chemistry and 13 papers in Cellular and Molecular Neuroscience. Recurrent topics in David A. Griffith's work include Receptor Mechanisms and Signaling (9 papers), Neurotransmitter Receptor Influence on Behavior (8 papers) and Cannabis and Cannabinoid Research (8 papers). David A. Griffith is often cited by papers focused on Receptor Mechanisms and Signaling (9 papers), Neurotransmitter Receptor Influence on Behavior (8 papers) and Cannabis and Cannabinoid Research (8 papers). David A. Griffith collaborates with scholars based in United States, Australia and United Kingdom. David A. Griffith's co-authors include Samuel J. Danishefsky, Jane M. Withka, John E. Bleasdale, Jessica Ward, Boris A. Chrunyk, David Cunningham, Alison E. Varghese, V. Thanabal, Xiayang Qiu and Brandon Pabst and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

David A. Griffith

50 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1

2010 723 citations Michelle Pacholec, John E. Bleasdale et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Griffith United States	22	1.2k	880	524	349	300	52	2.5k
Michael R. Jirousek United States	29	2.8k 2.3×	606 0.7×	739 1.4×	762 2.2×	536 1.8×	60	4.7k
Sameer S. Kulkarni Australia	23	1.5k 1.2×	470 0.5×	461 0.9×	626 1.8×	278 0.9×	46	2.4k
Lucia Biasutto Italy	30	1.4k 1.1×	198 0.2×	409 0.8×	236 0.7×	140 0.5×	61	2.1k
Simona Rapposelli Italy	33	1.1k 0.9×	803 0.9×	55 0.1×	463 1.3×	145 0.5×	126	3.0k
Bruce G. Szczepankiewicz United States	19	904 0.7×	386 0.4×	205 0.4×	199 0.6×	122 0.4×	32	1.4k
Andrea Galmozzi United States	19	1.0k 0.8×	481 0.5×	111 0.2×	374 1.1×	216 0.7×	31	1.8k
Hongguang Xia China	34	1.5k 1.2×	1.4k 1.6×	102 0.2×	216 0.6×	1.2k 3.9×	76	3.8k
Daniela Pizzirani Italy	22	717 0.6×	645 0.7×	254 0.5×	207 0.6×	84 0.3×	32	1.6k
Yukihiro Itoh Japan	30	2.3k 1.9×	487 0.6×	170 0.3×	69 0.2×	116 0.4×	77	3.0k
K.W. Nettles United States	30	1.5k 1.2×	410 0.5×	54 0.1×	194 0.6×	79 0.3×	54	2.9k

Countries citing papers authored by David A. Griffith

Since Specialization

Citations

This map shows the geographic impact of David A. Griffith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Griffith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Griffith more than expected).

Fields of papers citing papers by David A. Griffith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Griffith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Griffith. The network helps show where David A. Griffith may publish in the future.

Co-authorship network of co-authors of David A. Griffith

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Griffith. A scholar is included among the top collaborators of David A. Griffith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Griffith. David A. Griffith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aspnes, Gary E., Scott W. Bagley, Steven B. Coffey, et al.. (2023). 6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor. Bioorganic & Medicinal Chemistry Letters. 94. 129454–129454. 4 indexed citations

Limberakis, Chris, Aaron Smith, Scott W. Bagley, et al.. (2023). Convergent Syntheses of Isomeric Imidazolospiroketones as Templates for Acetyl-CoA Carboxylase (ACC) Inhibitors. The Journal of Organic Chemistry. 88(19). 13727–13740.

Eng, Heather, Yi‐An Bi, Mark A. West, et al.. (2021). Organic Anion–Transporting Polypeptide 1B1/1B3–Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro–In Vivo Evaluation in Cynomolgus Monkey. Journal of Pharmacology and Experimental Therapeutics. 377(1). 169–180. 15 indexed citations

Tess, David A., Heather Eng, Amit S. Kalgutkar, et al.. (2020). Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs. Journal of Medicinal Chemistry. 63(20). 11831–11844. 15 indexed citations

Plisson, Fabien, Timothy A. Hill, Huy N. Hoang, et al.. (2016). Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling. European Journal of Medicinal Chemistry. 127. 703–714. 20 indexed citations

Swedberg, Joakim E., Christina I. Schroeder, David P. Fairlie, et al.. (2016). Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro. Journal of Biological Chemistry. 291(30). 15778–15787. 8 indexed citations

Kok, W. Mei, Timothy A. Hill, Rink‐Jan Lohman, et al.. (2015). Cyclic penta- and hexa leucine peptides without N-methylation are orally absorbed. Queensland's institutional digital repository (The University of Queensland). 250. 1 indexed citations

Bandara, Nilantha, Alex Zheleznyak, David A. Griffith, et al.. (2015). Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging. Molecular Imaging and Biology. 18(1). 90–98. 13 indexed citations

Wallner, Markus, Ewald Kolesnik, Klemens Ablasser, et al.. (2015). Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium. Journal of Molecular and Cellular Cardiology. 89(Pt B). 365–375. 50 indexed citations

10.

Swedberg, Joakim E., Christina I. Schroeder, Thomas Durek, et al.. (2015). Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists. European Journal of Medicinal Chemistry. 103. 175–184. 21 indexed citations

11.

Nielsen, Daniel S., Huy N. Hoang, Rink‐Jan Lohman, et al.. (2014). Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable. Angewandte Chemie International Edition. 53(45). 12059–12063. 118 indexed citations

12.

Griffith, David A., Daniel W. Kung, William P. Esler, et al.. (2014). Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. Journal of Medicinal Chemistry. 57(24). 10512–10526. 60 indexed citations

13.

Eng, Heather, Raman Sharma, Thomas S. McDonald, et al.. (2013). Demonstration of the Innate Electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor. Drug Metabolism and Disposition. 41(8). 1470–1479. 20 indexed citations

14.

Miao, Zhuang, et al.. (2011). Excretion, Metabolism, and Pharmacokinetics of CP-945,598, a Selective Cannabinoid Receptor Antagonist, in Rats, Mice, and Dogs. Drug Metabolism and Disposition. 39(12). 2191–2208. 3 indexed citations

15.

Abraham, Anson K., Tristan S. Maurer, Amit S. Kalgutkar, et al.. (2011). Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor. The AAPS Journal. 13(2). 265–273. 9 indexed citations

16.

Hadcock, John R., Philip A. Carpino, Philip A. Iredale, et al.. (2010). Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist. BMC Pharmacology. 10(1). 9–9. 12 indexed citations

17.

Pacholec, Michelle, John E. Bleasdale, Boris A. Chrunyk, et al.. (2010). SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1. Journal of Biological Chemistry. 285(11). 8340–8351. 723 indexed citations breakdown →

18.

Dow, Robert L., John R. Hadcock, Dennis O. Scott, et al.. (2009). Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles. Bioorganic & Medicinal Chemistry Letters. 19(18). 5351–5354. 11 indexed citations

19.

Cao, Xuebing, Liang Li, John R. Hadcock, et al.. (2007). Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics. 323(1). 318–326. 82 indexed citations

20.

Doppalapudi, Venkata Ramana, Lingna Li, Teresa Aja, et al.. (2006). Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies™. Bioorganic & Medicinal Chemistry Letters. 17(2). 501–506. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact